ABT-737

Catalog No.S1002

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Cited by 212 Publications

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):435-449

PubMed: 29533784 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(1):84-97

PubMed: 30649895 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5770

PubMed: 31852899 ( click the link to review the publication )

EMBO J, 2019, 38(11)

PubMed: 30979778 ( click the link to review the publication )

Dev Cell, 2019, 51(2):277-291

PubMed: 31564612 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

J Cancer, 2019, 10(6):1466-1478

PubMed: 31031856 ( click the link to review the publication )

Thromb Haemost, 2019, 19(10):1665-1674

PubMed: 31493778 ( click the link to review the publication )

Eur J Immunol, 2019, 10.1002/eji.201948254

PubMed: 31411729 ( click the link to review the publication )

Phytomedicine, 2019, 64:153068

PubMed: 31419729 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )
J Bone Oncol, 2019, 19:100268

PubMed: 31832331 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:897-906

PubMed: 30774376 ( click the link to review the publication )

Platelets, 2019, 30(1):75-80

PubMed: 29125379 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5435

PubMed: 30575733 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(21):5458-5470

PubMed: 30021909 ( click the link to review the publication )

Oncogene, 2018, 37(39):5325-5339

PubMed: 29858601 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):994

PubMed: 30250198 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):199

PubMed: 29415991 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(6):465-474

PubMed: 29394130 ( click the link to review the publication )

Phytother Res, 2018, 32(6):1126-1134

PubMed: 29464855 ( click the link to review the publication )

Thromb Res, 2018, 171:22-30

PubMed: 30240944 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Oncotarget, 2018, 9(42):26834-26851

PubMed: 29928488 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )
Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28692422 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 29148970 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )

Asia Pac J Clin Oncol, 2017, 13(2):e144-e152

PubMed: 26552712 ( click the link to review the publication )

Oncotarget, 2017, 8(29):46801-46817

PubMed: 27086916 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1138-49

PubMed: 26467384 ( click the link to review the publication )
Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )

Sci Rep, 2016, 6:21264

PubMed: 26887909 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(51):85492-85501

PubMed: 27863431 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84594-84607

PubMed: 27829238 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83208-83222

PubMed: 27825124 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77815-77824

PubMed: 27780925 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Autophagy, 2015, 11(3):452-9

PubMed: 25715028 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )
Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12290-9

PubMed: 25829495 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:34

PubMed: 25852302 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):667-76

PubMed: 25434832 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: 25596561 ( click the link to review the publication )

Hepatol Res, 2015, 45(9):1023-1033

PubMed: 25297967 ( click the link to review the publication )

Exp Cell Res, 2015, 335(1):62-7

PubMed: 26024774 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 464(1):286-91

PubMed: 26116776 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36338-53

PubMed: 26462148 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(1):409-26

PubMed: 25565667 ( click the link to review the publication )

Oncotarget, 2015, 6(8):5582-96

PubMed: 25714024 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Autophagy, 2014, 10(10):1776-86

PubMed: 25126729 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5446-55

PubMed: 25208882 ( click the link to review the publication )
Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

J Immunother, 2014, 37(1):8-15

PubMed: 24316551 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 134(6):1311-5

PubMed: 25288466 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )
PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e702

PubMed: 23828565 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e762

PubMed: 23928701 ( click the link to review the publication )

Br J Cancer, 2013, 108(9):1870-8

PubMed: 23558901 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Stem Cells Transl Med, 2013, 2(9):690-702

PubMed: 23934910 ( click the link to review the publication )

Cancer Sci, 2013, 104(6):732-9

PubMed: 23421409 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

Cancer Gene Ther, 2013, 20(7):386-93

PubMed: 23788110 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )
Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Biomed Pharmacother, 2013, 67(7):583-91

PubMed: 23706691 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 437(4):565-72

PubMed: 23850692 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2013, 113(3):145-51

PubMed: 23557083 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

J Clin Invest, 2012, 122(6):2018-31

PubMed: 22622039 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(9):1508-20

PubMed: 22771494 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )
BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2011, 121(3):1053-63

PubMed: 21317538 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Am J Nephrol, 2011, 34(6):549-59

PubMed: 22123611 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

J Biol Chem, 2010, 285(26):19910-20

PubMed: 20421300 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Features

First-generation inhibitor of anti-apoptotic Bcl-2 proteins.

Targets

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. ^[1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. ^[2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. ^[3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. ^[4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	NXfJOJgxS2WubDDWbYFjcWyrdImgRZN{[Xl?	MkXWNlUxKG6PwrC=	NIj0eok4OiCq	NGP3TYlFVVOR	NH6wV3pk[XW\|ZXSgPVcmKGyxc4Ogc4YhfmmjYnnsbZR6KGmwIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIghSkOONjDzbXJPSQ>?	NVK3bJlOOjZ4NUeyPFg>
KG1a	NIWxXYlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFXJbpExNTFyIN88US=>	MkPTNlQhcA>?	MnzvSG1UVw>?	NFTBb5lKSzVyPUeuOlgh\|ryPLDDk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M2PNclI3PTV{N{Gy
Kasumi-1	NYPBfZJTS2WubDDWbYFjcWyrdImgRZN{[Xl?	M2XRRlAuOTBizszN	NYezZW5pOjRiaB?=	NVfreY9ETE2VTx?=	MVvJR\|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	Mn\1NlY2PTJ5MUK=
KG1a	M3PVeWFxd3C2b4Ppd{BCe3OjeR?=	NHHGZYQxNTFyIN88US=>	M1W5bFI1KGh?	NGfoV5ZFVVOR	NFTnTVJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NHvYcnozPjV3MkexNi=>
Kasumi-1	M3zadGFxd3C2b4Ppd{BCe3OjeR?=	NHH3SYUxNTFyIN88US=>	NHfZdYUzPCCq	NYnjNI1STE2VTx?=	M1nPZYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NGrHV3EzPjV3MkexNi=>
MC-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnWc4I1PS9zMD:yNEDPxE1?	M3;ZVVI1KGh?	M{nnN2ROW09?	M2S4d4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NWLlfnFFOjZ2NEe2NVU>
HN22	NWq1dnVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHGwXJAzNjVxNz61M\|IzNjVizszN	MkLBNlQhcA>?	NXL4fFdsTE2VTx?=	MoLtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MUOyOlQ1PzZzNR?=
MC-3	MYHBdI9xfG:\|aYOgRZN{[Xl?	MXK1M\|ExNzJyIN88US=>	M3HPVlI1KGh?	NGXKbnRFVVOR	MXzpcoR2[2W\|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m\|	MkL3NlY1PDd4MUW=
HN22	NVnFdFN5SXCxcITvd4l{KEG\|c3H5	MmPTNk42NzdwNT:yNk42KM7:TR?=	NYjmenplOjRiaB?=	MYjEUXNQ	NFjjVHBqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz	MXOyOlQ1PzZzNR?=
MOLT-4	NI\3TGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX2xNE02ODByIH7N	MV:3NkBp	MUTEUXNQ	NFnNNFZKSzVyPUCuNVk5KM7:TR?=	NITZO4gzPjN7MkOzNi=>
RS4;11	MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHW1dIcyOC13MECwJI5O	M4i5WFczKGh?	MmrjSG1UVw>?	M2roUGlEPTB;MD6wNFIh\|ryP	NY[3dWhPOjZ\|OUKzN\|I>
JURKAT	NGDGR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnlNVRROTBvNUCwNEBvVQ>?	NITpSVI4OiCq	M4TCZ2ROW09?	NELRSm9KSzVyPU[2JO69VQ>?	NHTMZXAzPjN7MkOzNi=>
CEM R	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPucYIyOC13MECwJI5O	NIXvcGI4OiCq	NGjNcpZFVVOR	NFq0eldKSzVyPUWuOEDPxE1?	NXP6VotzOjZ\|OUKzN\|I>
CEM S	MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlu5NVAuPTByMDDuUS=>	MVG3NkBp	M2Gw[WROW09?	NYO4OZhPUUN3ME2xNk4yKM7:TR?=	MYSyOlM6OjN\|Mh?=
MOLT-4	M3K2WGFxd3C2b4Ppd{BCe3OjeR?=	NFfZN\|QyOC1zMECwJI5O	NGm4R\|YzPCCq	MnT4SG1UVw>?	NVjVdY9T[2G3c3XzJJRp\SClbHXheoFo\SCxZjDCZ4wuOiCjbnSgeIhmKGSxd37y[Yd2dGG2aX;uJI9nKEKlbD34UEBidmRiTXPsMVE>	NUPs[W9LOjZ\|OUKzN\|I>
CEM S	MXXBdI9xfG:\|aYOgRZN{[Xl?	NUfOTYZTOTBvMUCwNEBvVQ>?	MkHZNlQhcA>?	MUPEUXNQ	MU\jZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?=	M3;nPVI3Ozl{M{Oy
JURKAT	M{TST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWP4VINSOTByLUGwNFAhdk1?	M{jjWVQ5KGh?	NV3vOnJsTE2VTx?=	NET5SVJKSzVyPUm1OeKyQS5\|IH7N	Mk\sNlYyPzJ{Nkm=
LOUCY	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3JNVAxNTFyMECgcm0>	NYD6fJh{PDhiaB?=	M3XzWGROW09?	NWTEfGxrUUN3ME2zNk45yrFzMD65JI5O	MYWyOlE4OjJ4OR?=
WM-115	NFfTeWdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVexNFDDqG6P	NXHaVGFUPzJiaB?=		NUXVZ2pJ\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC=	M{P0d\|I3OTF4N{e2
B16	M37hcmNmdGxiVnnhZoltcXS7IFHzd4F6	MYCxNFDDqG6P	MUm3NkBp		MnrR[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB?	NXewdJl2OjZzMU[3O\|Y>
HL-60	NFL6OGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYC3NkBp		NHj3bXZKSzVywrC9JFExNjdibl2=	NWHPZYVGOjZyNEW2NFk>
MOLM-13	NGPFOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlnkO\|IhcA>?		MV;JR\|UxyqB;IEK3Mlkhdk1?	NEPaRmozPjB2NU[wPS=>
OCI-AML3	NIjtWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXHtemZ6PzJiaB?=		M4rERmlEPTEEoE2gNVk2OCCwTR?=	NGfkU\|kzPjB2NU[wPS=>
BCWM.1	NGfqc3pCeG:ydH;zbZMhSXO\|YYm=	M{PQUlAuOS54IN88US=>	MX2yOEBp		M{fUUYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MkLpNlU5QTN{OUC=
MWCL-1	MkTlRZBweHSxc3nzJGF{e2G7	Mn7SNE0yNjZizszN	MV6yOEBp		MkTJbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NIWyUJMzPTh7M{K5NC=>
MM.1s	M33zRWFxd3C2b4Ppd{BCe3OjeR?=	NULGcnFSOC1zLk[g{txO	Mmn5NlQhcA>?		MoXmbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NF6yUZMzPTh7M{K5NC=>
HCT116	NXrNNZc5TnWwY4Tpc44hSXO\|YYm=	NHHSdJk{NzFyIN88US=>	NXjvSlNIOTMEoHlCpC=>	MnnTSG1UVw>?	Mn3GbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w	NWrBN5F1OjV5MUWwNlg>
HCT116 BAX BAK1 DKO	NH33eHhHfW6ldHnvckBCe3OjeR?=	NH3Ic4U{NzFyIN88US=>	NYLselFwOTMEoHlCpC=>	NF[zSIFFVVOR	MWPpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK\|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25?	MkOxNlU4OTVyMki=
HCT116	M3Pn[mZ2dmO2aX;uJGF{e2G7	M3PmXVExKM7:TR?=	NXjCUXdxOTMEoHlCpC=>	NYO0fW9XTE2VTx?=	MUPpcoNz\WG\|ZYOgS2ZRNUyFM1KgdJVv[3Sj	NFLhR4QzPTdzNUCyPC=>
HCT116 BAX BAK1 DKO	NFTW[GtHfW6ldHnvckBCe3OjeR?=	NXTPdGZ5OTBizszN	NWfrSGhkOTMEoHlCpC=>	NHLrd3dFVVOR	NF25e3lqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th	Mke3NlU4OTVyMki=
HCT116	MWDBeZRweGijZ4mgRZN{[Xl?	NV3SZYNzOTBizszN	MVWxNuKhcMLi	MkTDSG1UVw>?	NIDJZodqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>?	M3r2WVI2PzF3MEK4
HCT116 BAX BAK1 DKO	MoS3RZV1d3CqYXf5JGF{e2G7	MVmxNEDPxE1?	NUDyOJZ{OTMEoHlCpC=>	NELSbZVFVVOR	M4XIXYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm	NG\yXZAzPTdzNUCyPC=>
U937	NHizfJRCeG:ydH;zbZMhSXO\|YYm=	NITtcGIxNjF{NT2yJO69VQ>?	Mmn3NlQhcA>?		NYGydYw5\W6qYX7j[ZMhTEiDL2itNVEucW6mdXPl[EBieG:ydH;zbZM>	Ml3pNlU4OTRyMkS=
U937	MWfBdI9xfG:\|aYOgRZN{[Xl?	NVXCdGUzOC53IN88US=>	MUCyOEBp		Mlr2[Y5p[W6lZYOgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G\|cHHz[U0{KGG\|IIflcIwh[XNiTn;4ZUBt\X[nbB?=	NFTETpAzPTdzNECyOC=>
HL-60 AAA-Bcl-2	MYDBdI9xfG:\|aYOgRZN{[Xl?	M1vNSFAuPSEQvF2=	M2XxcFQ5KGh?		NF3sTW1KSzVyPUCuPFch\|ryv78{MbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NYW2dIdYOjV5MUG0OlA>
HL-60 EEE-Bcl-2	NGX3TZJCeG:ydH;zbZMhSXO\|YYm=	Mmq0NE02KM7:TR?=	M1L3clQ5KGh?		M{C4N2lEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	Moe5NlU4OTF2NkC=
U87	M1K3Z2Z2dmO2aX;uJGF{e2G7	MmDOOVAh\|ryP	M2TI[VI1KGh?		NEjI[Xhz\WS3Y3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJI9nKE2PUD2yMEBOVVBvMUSgZY5lKEKlbD2y	NUO3[3g{OjV4Nke2OlM>
K562	NIPSenFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MUexMVExKM7:TR?=	MXO0PEBp	MlnXSG1UVw>?	NHjHUnBKSzVyPUK2Mlch\|ryP	MmXGNlU2QTZ3NkG=
K562/Mcl -1-IRESBim	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDrWoZCUUN3ME25MlMh\|ryP	NWi5d4lwOjV3M{W5NFA>
K562/Bcl- 2-IRESBim	NH3tdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXUO\|dKSzVyPUCuN\|Uh\|ryP	NUPlT45vOjV3M{W5NFA>
Jurkat	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4m1eGlEPTB;MD62OkDPxE1?	NX20bFd7OjV3M{W5NFA>
JurkatΔBak	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWj2fW5DUUN3ME61NEDPxE1?	NHrxTXYzPTV\|NUmwNC=>
HL60/VCR	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWH3UYVVUUN3ME6xNFAh\|ryP	M1LiR\|I2PTN3OUCw
Kasumi-1	NXjIdW9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonSTWM2OD1yLkCxJO69VQ>?	Mm\ONlU2OzV7MEC=
Kasumi-1/ABT	M3rsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwNUGg{txO	MorYNlU2OzV7MEC=
THP-1	M3jZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmGxTWM2OD1zLkK3JO69VQ>?	MX6yOVU{PTlyMB?=
U937	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTXTWM2OD13LkK5JO69VQ>?	NG\2T3UzPTV\|NUmwNC=>
C1498	NInFe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTGTWM2OD14LkGzJO69VQ>?	NEfpNFEzPTV\|NUmwNC=>
RPMI 8226	NIrVWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXJepBKSzVyPUCuNlUh\|ryP	M{fzZlI2PTN3OUCw
MM.1S	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvr[4xKSzVyPUCuOFAh\|ryP	M4rZV\|I2PTN3OUCw
NCI-H929	M{e4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\KNGlEPTB;MUWuNlEh\|ryP	NHTEUY4zPTV\|NUmwNC=>
U266	NXrMcGxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwNkig{txO	NWL3[HdFOjV3M{W5NFA>
MCF-7	NYG5cZltS2WubDDWbYFjcWyrdImgRZN{[Xl?	MUC1JO69VQ>?	NGG0Z3I1QCCq	NHrq[W9FVVOR	NV;XbXN{\W6qYX7j[ZMhfGinIIPlcpNqfGm4aYT5JJRwKG:{IILh[IlifGmxbh?=	NVPx[ItwOjV2MEmxNlQ>
MCF-7	MnqyRZBweHSxc3nzJGF{e2G7	NE\lNHM2KM7:TR?=	M4rMUlQwOjRxNEigbC=>	NEHoNmFFVVOR	MmKybY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC=	M2K5RVI2PDB7MUK0
MCF-7	MnTlSpVv[3Srb36gRZN{[Xl?	MUi1JO69VQ>?	MWGyOEBp	Ml7xSG1UVw>?	M2q4ZYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	NH;iWXozPTRyOUGyOC=>
MDA-MB 231	NInmTopHfW6ldHnvckBCe3OjeR?=	NV\YNXVKPSEQvF2=	MoPTNlQhcA>?	MYDEUXNQ	M2e2fIVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	M2fjVVI2PDB7MUK0
ZR-75-1	NYj1VnJJTnWwY4Tpc44hSXO\|YYm=	MnTTOUDPxE1?	MoTsNlQhcA>?	MnzQSG1UVw>?	MVLlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	MlvuNlU1ODlzMkS=
A549	NIDBVppE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3r3ZVAuOjBizszN	MWG3NkBp	NGjmb\|ZFVVOR	NYrTSVJY\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	NYPOfVg1OjV\|OEi3OlI>
H1299	NUm2fY53S2WubDDWbYFjcWyrdImgRZN{[Xl?	NVP5dZhFOC1{MDFOwG0>	M3vpSVczKGh?	M{OwS2ROW09?	M3PsWoRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	M4nrVVI2Ozh6N{[y
HO-8910	NUPaOldUS2WubDDWbYFjcWyrdImgRZN{[Xl?	MYOwMVIxKM7:TR?=	MXS3NkBp	M1Pz[mROW09?	M2TXOIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	M3fsXFI2Ozh6N{[y
HT-29	NFu0OpVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mn3ENE0zOCEQvF2=	MmPBO\|IhcA>?	NV7JPJQyTE2VTx?=	NXL5bpVk\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	MXuyOVM5QDd4Mh?=
HCT-116	NHnwU5VE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NX3nc3g{OC1{MDFOwG0>	MUm3NkBp	M2fOUWROW09?	NIDWUpll\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NFvYbnYzPTN6OEe2Ni=>
A549	NFTrb4FCeG:ydH;zbZMhSXO\|YYm=	NIGwVYYzOCEQvF2=	MlWxOFghcA>?	NHywbphFVVOR	MY\pcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	M4\FdFI2Ozh6N{[y
H1299	NF33[nhCeG:ydH;zbZMhSXO\|YYm=	NHWzUZEzOCEQvF2=	NIn1WIQ1QCCq	MYfEUXNQ	MX;pcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	MWSyOVM5QDd4Mh?=
Sc-1	MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MXWwMlAxODFvMTFOwG0>	MoXDPVYhcA>?		NFHlOIFl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MnLSNlU{PzN3MEi=
OcI-LY18	MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M{O4T\|AvODByMT2xJO69VQ>?	MUi5OkBp		M4HSb4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MlfqNlU{PzN3MEi=
RL	MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M{ntd\|AvODByMT2xJO69VQ>?	NYKzTWF3QTZiaB?=		NHO2XlFl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MYKyOVM4OzVyOB?=
RKO	M2[5WWNmdGxiVnnhZoltcXS7IFHzd4F6	MXiwMVExKM7:TR?=	MXuyOQKBkWkEoB?=	NIixVG1FVVOR	MUfJR\|UxRuLCiUK15qCKyrWP	MlL0NlU{ODR\|OEO=
Caco-2	NV:0SpdsS2WubDDWbYFjcWyrdImgRZN{[Xl?	MUSwMVExKM7:TR?=	M4HuWlI16oDLaNMg	NXK1[oF4TE2VTx?=	M37uNmlEPTB;MUmuO-KBkcL3TR?=	MWSyOVMxPDN6Mx?=
DLD1	NFfzUVRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MWWwMVExKM7:TR?=	NYT4fYVtOjUkgJnoxsA>	M2e3[mROW09?	MWjJR\|UxRTF6Lke45qCKyrWP	NWqxSph7OjV\|MESzPFM>
LS411N	M4nzOWNmdGxiVnnhZoltcXS7IFHzd4F6	NYTjeY1JOC1zMDFOwG0>	MVuyOQKBkWkEoB?=	MljSSG1UVw>?	MUXJR\|UxRTFzLkS35qCKyrWP	NVfhbIQzOjV\|MESzPFM>
SW620	M1\tUGNmdGxiVnnhZoltcXS7IFHzd4F6	NIDv[4UxNTFyIN88US=>	NVvMXnZQOjUkgJnoxsA>	MVfEUXNQ	MVLJR\|UxRTF{LkK05qCKyrWP	MWiyOVMxPDN6Mx?=
HCT116	M2Lse2NmdGxiVnnhZoltcXS7IFHzd4F6	M4nwN\|AuOTBizszN	Mn;6NlTjiImqwrC=	MlfZSG1UVw>?	M4L4UWlEPTB;MkCuOFnjiIoEtV2=	M2j0PVI2OzB2M{iz
HaCaT	MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1yzb\|AvOS9zL{GwJO69VQ>?	NVLjfoVvOjRiaB?=	MkPHSG1UVw>?	MoHW[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NEXJNGEzPTJzMEe5OS=>
A5-RT3	NHrYW29E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHHRSlgxNjFxMT:xNEDPxE1?	M1vFUFI1KGh?	M2O5OWROW09?	M2fpcYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NUPkWmJ4OjV{MUC3PVU>
HaCaT	NIfYWYNHfW6ldHnvckBCe3OjeR?=	MnTnNVDjiIoQvF2=	NHXreJAzPC92ODDo	NUHyUItvTE2VTx?=	MlXKbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w	NFzB[pozPTJzMEe5OS=>
A5-RT3	M{PQUGZ2dmO2aX;uJGF{e2G7	MoLRNVDjiIoQvF2=	M{\kflI1NzR6IHi=	M2jqZmROW09?	NFPsfmVqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36=	MVSyOVIyODd7NR?=
A5-RT3	M2nzeGZ2dmO2aX;uJGF{e2G7	NGizU402KM7:TR?=	NWn1ZXhMPiCq	M3XDSGROW09?	NFzhXZNqdmS3Y3XzJJRp\SC{ZXzlZZNmKG:oIH3peI9kcG:wZILpZYwheHKxdHXpcpMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDzeZJ3cX[jbDDpckBiKGOjc4Dhd4UucW6mZYDlcoRmdnRibXHucoVz	NV7DUJB5OjV{MUC3PVU>
U266	M1fhT2Z2dmO2aX;uJGF{e2G7	NI\zbIM2ODBxN{WwJI5O	MlnDNlQwPDhiaB?=	NHjGUmNFVVOR	MUDkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2=	NIWwepgzPTJyOEi4PC=>
RPMI8226	MmHVSpVv[3Srb36gRZN{[Xl?	MWm1NFAwPzVyIH7N	NIK1SHEzPC92ODDo	MX;EUXNQ	MkW1[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt	NH;OWpEzPTJyOEi4PC=>
MM.1S	NUnlRZRJTnWwY4Tpc44hSXO\|YYm=	MXK1NFAwPzVyIH7N	NFLS[lgzPC92ODDo	NVPjdFBMTE2VTx?=	NVHt[Wk{\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju	MX:yOVIxQDh6OB?=
Clone A	NUHUSFB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;NNE4z6oDVNkCg{txO	MWe3NkBp	NITRVYdFVVOR	MoPlTWM2OD15LkWg{txO	NFjRUHUzPTJyOEi4Ni=>
CX-1	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvZUplMOC5{4pETOlAh\|ryP	M1nmWFczKGh?	MlfWSG1UVw>?	NG\FXmRKSzVyPUGuPEDPxE1?	NYrkUZU3OjV{MEi4PFI>
LS174T	MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nMZ\|AvOuLCk{[wJO69VQ>?	M3HzeVczKGh?	M3;Je2ROW09?	MlHBTWM2OD1zOD6zJO69VQ>?	MnnPNlUzODh6OEK=
HT29	M4\FcWFxd3C2b4Ppd{BCe3OjeR?=	M3m0SVEwPS9zMDFOwG0>	MVe0PEBp		MWnjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MXqyOVE6OjF6OB?=
SW480	MoPJRZBweHSxc3nzJGF{e2G7	NHXmcWoyNzVxMUCg{txO	NVjVV4h2PDhiaB?=		MlzLZ4F2e2W\|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MmjJNlUyQTJzOEi=
Colo205	MXHBdI9xfG:\|aYOgRZN{[Xl?	MWGxM\|UwOTBizszN	NGroRoU1QCCq		M4O3eYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGjzZ3AzPTF7MkG4PC=>
Caco2	MlPLRZBweHSxc3nzJGF{e2G7	MUmxM\|UwOTBizszN	NVGyUVBtPDhiaB?=		MYrjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFq4UWgzPTF7MkG4PC=>
PCI-13	M4LVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoXuO\|IhcA>?	NUDaeWdMTE2VTx?=	MUnHTVUxRTF3INMxJFEvQCEQvF2=	MlSwNlUyOzl\|OEe=
PCI-15B	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFi4SFQ4OiCq	NHTPcodFVVOR	Mk\5S2k2OD1zMTFCtUA1NjVizszN	NFLydJAzPTF\|OUO4Oy=>
UM-SCC22B	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFrMNlI4OiCq	M1TVT2ROW09?	NVHYNGpJT0l3ME2xPUDDuSB{Lkmg{txO	M1TqPVI2OTN7M{i3
UM-SCC47	NF7COXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4Lm[\|czKGh?	MmT3SG1UVw>?	MkGxS2k2OD1zOTFCtUAyOi5\|IN88US=>	NGqxOJYzPTF\|OUO4Oy=>
93-VU-147T	NEPaOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkXxO\|IhcA>?	NEXm[2ZFVVOR	NY\SWnVIT0l3ME20MlMhyrFiMz61JO69VQ>?	M1nQbFI2OTN7M{i3
UD-SCC2	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWjac4ZyPzJiaB?=	MofFSG1UVw>?	MkGwS2k2OD1{ODFCtUAzNjlizszN	NF\iVYozPTF\|OUO4Oy=>
UPCI:SCC90	M1L3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2XXZ\|czKGh?	MkKzSG1UVw>?	NVvmVnF[T0l3ME22MlYhyrFiMT61JO69VQ>?	M4jVdVI2OTN7M{i3
RPMI-8226	MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MUSxNlUwOjVyL{WwNEBvVQ>?	MYO0PIjDqA>?	NETydpdFVVOR	NVfsfFBS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFG4[lAzPTByOEKwNi=>
OPM-2	NFS2WFBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M4qwXVEzPS9{NUCvOVAxKG6P	NXrDZ4k5PDiqwrC=	MV;EUXNQ	MlfG[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MVOyOVAxQDJyMh?=
RPMI-8226	NUCzUXFtSXCxcITvd4l{KEG\|c3H5	MV6xNlUwOjVyL{WwNEBvVQ>?	NX\xZZFrPDiqwrC=	NUX2WY5TTE2VTx?=	Mn3tbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NV\GR2w6OjVyMEiyNFI>
OPM-2	NUTsUpFKSXCxcITvd4l{KEG\|c3H5	MUOxNlUwOjVyL{WwNEBvVQ>?	NE\TU2E1QGkEoB?=	NWnm[ZYzTE2VTx?=	M4Xab4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NYH6PHVPOjVyMEiyNFI>
COG-LL-319	M3yxWWZ2dmO2aX;uJGF{e2G7	MljqNVAxKG6P	M33kbFEwOy94IHi=	MojZSG1UVw>?	NVLaRYxMcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?=	MXiyOFk2OTR5Mh?=
RS4;11	MXfGeY5kfGmxbjDBd5NigQ>?	M3P5UVExOCCwTR?=	MWSxM\|MwPiCq	Mo\JSG1UVw>?	NYLJNGhOcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?=	M1WzPVI1QTVzNEey

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

In vivo

In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. ^[1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. ^[2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Fluorescence polarization assays: Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research: ^[4]	- Collapse Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 Concentrations: 0.001-10 μM Incubation Time: 48 hours Method: SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%) Dosages: 20 and 30 mg/kg Administration: For intraperitoneal (i.p.) every day (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% Propylene glycol, 5% Tween 80, 65% D5W For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download ABT-737 SDF

Molecular Weight	813.43
Formula	C₄₂H₄₅ClN₆O₅S₂
CAS No.	852808-04-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?
Answer:
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 212 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 212 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)